. Author manuscript; available in PMC: 2017 Jun 28.

Published in final edited form as: Genet Med. 2016 Feb 11;18(9):863–868. doi: 10.1038/gim.2015.184

Table 3.

Median overall survival, cancer-specific survival and hazard ratios corrected for age and stage at diagnosis

	Overall survival (mo)		HR (95%CI)	p-value	Cancer-specific survival (mo)		HR (95%CI)	p-value
	LS	MLH1-hm	HR (95%CI)	p-value	LS	MLH1-hm	HR (95%CI)	p-value
Stage I	NR	51	^*	^*	NR	NR	^*	^*
Stage II	NR	59	3.97 (0.85–18.5)	0.079	NR	NR	1.07 (0.08–13.6)	0.96
Stage III	71	32	1.08 (0.28–4.18)	0.91	71	NR	1.11 (0.22–5.64)	0.90
Stage IV	23.5	17	2.07 (0.32–13.5)	0.45	23.5	17	2.07 (0.32–13.5)	0.45
Overall	NR	45	1.96 (0.89–4.92)	0.095	NR	NR	1.33 (0.46–3.83)	0.60

HR>1 signifies that LS has better survival than MLH1-hm patients.

Not enough events to calculate.

CI=confidence interval; HR=hazard ratio; Mo=months; NR=not reached.